Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2016 17:30

RNS Number : 9044W
AstraZeneca PLC
29 April 2016
 

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

 

Results of Annual General Meeting held on 29 April 2016

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015

 

924,514,473

99.61

3,665,459

0.39

928,179,932

73.40%

8,998,621

2

To confirm dividends

 

933,191,043

99.69

2,915,972

0.31

936,107,015

74.03%

1,071,537

3

To re-appoint KPMG LLP, London as Auditor

 

929,918,594

99.56

4,151,154

0.44

934,069,748

73.87%

3,108,804

4

To authorise the Directors to agree the remuneration of the Auditor

 

934,984,319

99.89

988,556

0.11

935,972,875

74.02%

1,204,865

5a

To re-elect Leif Johansson as a Director

 

861,678,834

94.69

48,321,545

5.31

910,000,379

71.96%

27,177,942

5b

To re-elect Pascal Soriot as a Director

 

935,167,473

99.93

697,471

0.07

935,864,944

74.01%

1,342,796

5c

To re-elect Marc Dunoyer as a Director

 

931,875,086

99.58

3,920,615

0.42

935,795,701

74.00%

1,380,982

5d

To re-elect Cori Bargmann as a Director

 

935,157,654

99.93

635,873

0.07

935,793,527

74.00%

1,384,110

5e

To re-elect Geneviève Berger as a Director

 

935,199,102

99.93

622,099

0.07

935,821,201

74.00%

1,356,436

5f

To re-elect Bruce Burlington as a Director

 

933,026,505

99.70

2,762,355

0.30

935,788,860

74.00%

1,389,088

5g

To re-elect Ann Cairns as a Director

 

933,220,149

99.72

2,618,183

0.28

935,838,332

74.01%

1,339,989

5h

To re-elect Graham Chipchase as a Director

 

919,686,570

98.97

9,526,012

1.03

929,212,582

73.48%

7,965,366

5i

To re-elect Jean-Philippe Courtois as a Director

 

933,177,891

99.72

2,593,420

0.28

935,771,311

74.00%

1,406,637

5j

To re-elect Rudy Markham as a Director

 

923,984,532

98.74

11,766,347

1.26

935,750,879

74.00%

1,427,442

5k

To re-elect Shriti Vadera as a Director

 

927,479,182

99.11

8,287,726

0.89

935,766,908

74.00%

1,410,552

5l

To re-elect Marcus Wallenberg as a Director

 

870,828,312

95.76

38,511,577

4.24

909,339,889

71.91%

27,837,158

6

To approve the Annual Report on Remuneration for the year ended 31 December 2015

836,396,151

89.61

96,959,428

10.39

933,355,579

73.81%

3,822,290

7

To authorise limited EU political donations

 

908,106,542

97.83

20,185,176

2.17

928,291,718

73.41%

8,886,009

8

To authorise the Directors to allot shares

 

849,809,843

90.97

84,303,774

9.03

934,113,617

73.87%

3,064,122

9

To authorise the Directors to disapply pre-emption rights

 

922,425,478

98.82

11,009,374

1.18

933,434,852

73.82%

3,742,888

10

To authorise the Company to purchase its own shares

 

926,166,577

98.96

9,722,078

1.04

935,888,655

74.01%

1,289,613

11

To reduce the notice period for general meetings

 

829,946,353

88.85

104,116,202

11.15

934,062,555

73.87%

3,115,081

 

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

29 April 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUGACUPQGAB
Date   Source Headline
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for
28th Aug 20197:00 amRNSBreztri Aerosphere Phase III ETHOS trial met
22nd Aug 20197:00 amRNSRoxadustat approved in China for the treatment of
22nd Aug 20197:00 amRNSAstraZeneca agrees to buy US FDA Priority Review
21st Aug 20197:00 amRNSUpdate on the Phase III NEPTUNE trial
20th Aug 20197:00 amRNSFarxiga met primary endpoint in landmark Phase III
19th Aug 20197:00 amRNSDirectorate Change
14th Aug 20197:00 amRNSLynparza Phase III PAOLA-1 trial met primary endpo
14th Aug 20197:00 amRNSCalquence granted US Breakthrough Therapy Designat
9th Aug 20199:28 amRNSAmendment: Tagrisso significantly improves overall
9th Aug 20197:00 amRNSTagrisso significantly improves overall survival
7th Aug 20197:00 amRNSLynparza Phase III PROfound trial in HRR*
5th Aug 20197:00 amRNSForxiga label updated in the EU in type-2 diabetes
1st Aug 20193:00 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSAZN: H1 2019 Results
15th Jul 20197:00 amRNSUpdate on US regulatory decision for Farxiga
12th Jul 20197:00 amRNSImfinzi granted US Orphan Drug Designation for
1st Jul 20193:00 pmRNSTotal Voting Rights
1st Jul 20197:00 amRNSForxiga receives positive EU CHMP opinion for
1st Jul 20197:00 amRNSFasenra receives positive EU CHMP opinion for self
27th Jun 20197:00 amRNSImfinzi improves overall survival at interim
19th Jun 20197:00 amRNSBreztri Aerosphere (PT010) approved in Japan for
19th Jun 20197:00 amRNSLynparza approved in Japan for 1st-line
19th Jun 20197:00 amRNSBevespi Aerosphere approved by the Japanese
18th Jun 20197:00 amRNSLynparza approved in the EU for 1st-line
17th Jun 20197:00 amRNSCalquence significantly prolonged the time patient
12th Jun 20194:45 pmRNSPublication of a Prospectus
6th Jun 20197:00 amRNSCalquence Phase III ELEVATE-TN trial met primary
5th Jun 201912:36 pmEQSHardman & Co Research: AstraZeneca: Where has all the cash gone?
3rd Jun 20193:00 pmRNSBlock listing Interim Review
3rd Jun 20193:00 pmRNSTotal Voting Rights
3rd Jun 20197:00 amRNSLynparza nearly doubled time patients lived with
10th May 20197:00 amRNSPooled analyses of the roxadustat global Phase III
8th May 20192:00 pmRNSDirector/PDMR Shareholding
8th May 201911:00 amRNSDirector Declaration
8th May 20197:00 amRNSTrastuzumab deruxtecan demonstrated clinically
7th May 20197:00 amRNSCalquence PhIII ASCEND trial met primary endpoint
3rd May 20197:00 amRNSQternmet XR approved in the US for type-2 diabetes
1st May 20193:00 pmRNSTotal Voting Rights
1st May 201912:00 pmRNSDirector/PDMR Shareholding
29th Apr 20197:00 amRNSLynparza receives positive EU CHMP opinion for 1st
26th Apr 20195:45 pmRNSResult of AGM
26th Apr 20197:00 amRNSAZN: Q1 2019 Results
10th Apr 20197:00 amRNSLynparza approved in EU for the treatment of germl
9th Apr 20194:10 pmEQSHardman & Co Research: Global Pharmaceuticals: 2018 industry sales
4th Apr 20191:30 pmRNSHolding(s) in Company
3rd Apr 201910:00 amRNSDirector/PDMR Shareholding
2nd Apr 20193:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.